Genetic Screening and Testing

Before you consider any testing, you should consider the question, “How will this information affect how I manage my pregnancy?” Your answer to that question will affect how you view these tests. Your choice of testing is personal.

If you do elect to undergo testing, you should understand the difference between a screening test, which gives a likelihood of there being an abnormality, versus a diagnostic test, which provides you with a definite diagnosis.

During your pregnancy, you will be given several options for genetic testing. Your choice of test depends on your individual desires and your risk of having a baby with a chromosomal abnormality. There are two general types of tests: screening tests and diagnostic test. Tests like the AFP4 and the First Trimester NT Screen are screening tests, which assess the likelihood of delivering a baby having Down’s Syndrome, as opposed to a diagnostic test, such as the CVS or amniocentesis, which will give a definite diagnosis (but also carries a small risk of miscarriage). The screening test can’t tell for certain that your baby is affected. However, it can help someone decide whether or not to have a diagnostic test. Down’s Syndrome represents most couples’ primary genetic concern because this is one of the most common chromosomal abnormalities that can survive to live birth. Every woman has a risk of giving birth to a baby with Down’s Syndrome and this risk increases with age. Your chance of having a baby with Down’s Syndrome at age 25 is 1/1,350, at age 30 is 1/900, at age 35 is 1/360 and at age 40 is 1/100. The majority of Down’s Syndrome children are born to women under the age of 35 because more babies are born to younger women. The tests below are available to determine your risk of having a child with abnormal chromosomes and particularly, Down’s Syndrome. You have the opportunity to choose the type of testing that meets your needs. You should consider the differences between a screening test that determines whether you have a pregnancy at greater risk for chromosomes of your child. The screening tests are risk-free to your pregnancy. The definitive tests do contain certain risks to your pregnancy. You should also consider how accurate (sensitive) the tests are and what you will do with the results. See the detailed description below for more information.

Screening Tests


1st Trimester NT Screen

Involves an ultrasound of the fetus to measure the nuchal translucency (thickness of scruff of the fetus’ neck) combined with the blood from mother (Free Beta hCG and PAPP-A)
Sensitivity >90%
Performed at 11 to 13 6/7 weeks
Risk none known to mother or fetus
Results available in less than 7 business days Tests for the likelihood of chromosomal abnormalities such as Down’s Syndrome and Trisomy 18, does not include a screening test for neural tube defects (Spina Bifida). This is tested at 16 weeks with a simple blood test.


Maternal Serum Screening (AFP4)


Involves obtaining blood from mother
Sensitivity 85%, high false positive rate
Performed at 16 to 20 weeks
Risk none known to mother or fetus
Results available in 7 to 10 business days Tests for the likelihood of chromosomal abnormalities such as Down’s Syndrome and Trisomy 18. It includes a screening test for neural tube defects (Spina Bifida). This is tested at 16 weeks with a simple blood test.

Diagnostic Tests


Chorionic Villus Sampling (CVS)
Involves obtaining placental tissue through the cervix or abdomen.
Sensitivity 97 to 100%
Performed at 9 to 12 weeks
Risk of fetal loss approximately 1/100 (1%)
Results available in 7 to 10 business days A diagnostic test of fetal chromosomes, does not include a screening test for neural tube defects (Spina Bifida). This is tested at 16 weeks with a simple blood test.


Amniocentesis

Involves obtaining fluid from around the fetus by placing a needle through the mother’s abdomen. Sensitivity is close to 100%
Performed at 16 to 18 weeks
Risk of fetal loss approximately 1 in 500 (0.06%) Results available in 10 to 14 business days A diagnostic test of fetal chromosomes. The amniotic fluid is analyzed to screen for neural tube defects (Spina Bifida).

Screening Test (not a "first line" test)


Level II Ultrasound – screening test, but not a “first line” test More stringent ultrasound, focusing on markers for chromosomal problems Sensitivity varies, likely 30 – 50% Performed at 20 weeks Risk none known to mother or fetus Results available immediately

Email This Page Print This Page Save As PDF Back to Homepage
CONTACT | PRIVACY | FAQ |
Copyright ©2012
Obstetrics & Gynecology of Atlanta
1100 Johnson Ferry Road NE,
Suite 800, Center 2
Atlanta, Georgia 30342